 |
 |
Hoffman-La Roche
In December 2008, Synta and Roche formed a strategic alliance to discover,
develop, and commercialize small-molecule drugs targeting a novel family of ion
channels that are critical to immune cell function, known as calcium
release-activated calcium modulator (CRACM) channels. The goal is to develop a
novel category of oral, disease-modifying agents for the treatment of
rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD),
allergy, transplant rejection, and other autoimmune diseases and inflammatory
conditions.
Under the terms of the agreement, Roche will fund research to be conducted by
Synta during an initial two-year research period. Roche will receive worldwide
rights to develop and commercialize certain products identified prior to the
end of this research period. Synta retains certain co-development and
co-promotion rights. All preclinical, clinical, and commercial costs will be
paid by Roche.
In Q1 2009, Synta received a $16 million upfront cash license fee. In addition
to committed research funding over the two year term, Synta is also eligible to
receive additional payments, for each of three licensed products, should
specified development and commercialization milestones be successfully
achieved. Development milestones across multiple indications of up to $245
million could be earned for the first product, and up to half of this amount
could be earned for each of the second and third products. Commercialization
milestones of up to $170 million could be earned for each of three products.
Synta will receive tiered royalties on sales of all approved, marketed
products.
View press release
[Top of page]
|
|
